Aino Health AB (AINO) Fair Value & Analysis
Healthcare · SE · Market cap 39.9M SEK
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 57 days ago
Share price +17.9% over the past month.
Below-average quality, screening 66% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (kr 0.2890). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.
How to read this chart
60‑month range kr 0.1000 – kr 1.73 · fair‑value band kr 0.2890 – kr 0.4760 · the kr 0.2300 price screens below the kr 0.3825 fair value. Dashed = 300-day average. As of Jun 23, 2026.
Analysis
Aino Health AB (AINO) currently trades at kr 0.2300, while our model-based Fair Value estimate is kr 0.3825, implying the stock looks roughly 66.3% undervalued today. The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Aino Health AB generated revenue of 24.3M SEK at a net margin of -32.0%. Revenue declined 25.0% year over year. Net debt stands at 2.5M SEK. Fundamentals as of Jun 23, 2026
Our scenario range runs from kr 0.2890 (bear case) to kr 0.4760 (bull case); at kr 0.2300, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 98% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at 66%, AINO screens cheaper than that median.
Notify me when AINO reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jun 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Aino Health AB (publ) develops and provides digital SaaS platforms and consulting services focused on workplace health management and operational efficiency for organizations.
Full company description
Aino Health AB (publ) develops and provides digital SaaS platforms and consulting services focused on workplace health management and operational efficiency for organizations. It offers HealthManager, a cloud-based system that supports company management in monitoring employee well-being, managing staff turnover, and reducing sick leave, while ensuring compliance with regulations such as GDPR. The company also provides ongoing consulting services for onboarding and implementation of HealthManager, as well as process optimization and preventive measures for workplace health. It serves personnel managers, business leaders, and employees. The company was incorporated in 2016 and is based in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aino Health AB reported revenue of kr 26.1M in FY2025 versus kr 23.0M in FY2021, a compound +3.2%/yr. Reported net income was −kr 6.1M in FY2025.
Watch AINO: get an alert when its fair value changes →
Peer Group
Health Information Services · 127 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $241.51 | $91.49 | -62% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $105.50 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | -69% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.99 | $25.91 | +4% |
| Privia Health Group PRVA | $21.54 | $5.26 | -76% |
Compare Aino Health AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aino Health AB (AINO) overvalued or undervalued?
What is the fair value of AINO?
What is the quality score of AINO?
What is the revenue of Aino Health AB (AINO)?
What is the net profit margin of AINO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Aino Health AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.